Abstract
Idiosyncratic adverse drug reactions (IADRs) cause a broad range of clinically severe conditions of which drug induced liver injury (DILI) in particular is one of the most frequent causes of safety-related drug withdrawals. The underlying cause is almost invariably formation of reactive metabolites (RM) which by attacking macromolecules induce organ injuries. Attempts are being made in the pharmaceutical industry to lower the risk of selecting unfit compounds as clinical candidates. Approaches vary but do not seem to be overly successful at the initial design/synthesis stage. We review here the most frequent categories of mechanisms for RM formation and propose that many cases of RMs encountered within early ADME screening can be foreseen by applying chemical and metabolic knowledge. We also mention a web tool, SpotRM, which can be used for efficient look-up and learning about drugs that have recognized IADRs likely caused by RM formation.
Keywords: Reactive metabolite, drug safety, hepatotoxicity, idiosyncratic adverse drug reaction, web application, structural alerts, bioactivation
Mini-Reviews in Medicinal Chemistry
Title:On Mechanisms of Reactive Metabolite Formation from Drugs
Volume: 13 Issue: 5
Author(s): Alf Claesson and Ola Spjuth
Affiliation:
Keywords: Reactive metabolite, drug safety, hepatotoxicity, idiosyncratic adverse drug reaction, web application, structural alerts, bioactivation
Abstract: Idiosyncratic adverse drug reactions (IADRs) cause a broad range of clinically severe conditions of which drug induced liver injury (DILI) in particular is one of the most frequent causes of safety-related drug withdrawals. The underlying cause is almost invariably formation of reactive metabolites (RM) which by attacking macromolecules induce organ injuries. Attempts are being made in the pharmaceutical industry to lower the risk of selecting unfit compounds as clinical candidates. Approaches vary but do not seem to be overly successful at the initial design/synthesis stage. We review here the most frequent categories of mechanisms for RM formation and propose that many cases of RMs encountered within early ADME screening can be foreseen by applying chemical and metabolic knowledge. We also mention a web tool, SpotRM, which can be used for efficient look-up and learning about drugs that have recognized IADRs likely caused by RM formation.
Export Options
About this article
Cite this article as:
Claesson Alf and Spjuth Ola, On Mechanisms of Reactive Metabolite Formation from Drugs, Mini-Reviews in Medicinal Chemistry 2013; 13 (5) . https://dx.doi.org/10.2174/1389557511313050009
DOI https://dx.doi.org/10.2174/1389557511313050009 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bile Acids and Derivatives, Their Nuclear Receptors FXR, PXR and Ligands: Role in Health and Disease and Their Therapeutic Potential
Anti-Cancer Agents in Medicinal Chemistry The Role of Melatonin in the Immuno-Neuro-Psychology of Mental Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics The Brain-Immune-Gut Triangle: Innate Immunity in Psychiatric and Neurological Disorders
Current Immunology Reviews (Discontinued) A Primary Reduced TCA Flux Governs Substrate Oxidation in T2D Skeletal Muscle
Current Diabetes Reviews Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
Current Medicinal Chemistry Subject Index To Volume 8
Current Pharmaceutical Design Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial
Current Vascular Pharmacology Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Editorial [(Drugs and the Upper and Lower Gastrointestinal Tract: From Inflammation To Malignancy)
Current Drug Metabolism Regulation of Angiogenesis by the Kallikrein-Kinin System
Current Pharmaceutical Design Design and Synthesis of 2-(Arylmethylideneamino) Isoindolines as New Potential Analgesic and Anti-Inflammatory Agents: A Molecular Hybridization Approach
Current Pharmaceutical Design Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain
Current Neuropharmacology Immunomodulation in Polytrauma and Polymicrobial Sepsis - Where Do We Stand?
Recent Patents on Inflammation & Allergy Drug Discovery Ulcerative Colitis: Pathogenesis
Current Drug Targets Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety Better Targeting Melanoma: Options Beyond Surgery and Conventional Chemotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Vitamin D Supplementation and Cancer: Review of Randomized Controlled Trials
Anti-Cancer Agents in Medicinal Chemistry Understanding Trastuzumab Resistance in HER2 Positive Breast Cancer and Further Therapeutic Options
Current Cancer Therapy Reviews ADR in Journals: Are They Translated into Regulatory Frameworks?
Current Drug Safety